Sagar D. Sardesai, MBBS, discusses the phase 3 ELAINE-3 trial evaluating lasofoxifene plus abemaciclib in ESR1-mutant, ER-positive, HER2-negative breast cancer.
Sagar D. Sardesai, MBBS
Advertisement
Articles by Sagar D. Sardesai, MBBS
Sagar D. Sardesai, MBBS, discusses the phase 3 ELAINE-3 trial evaluating lasofoxifene plus abemaciclib in ESR1-mutant, ER+/HER2- metastatic breast cancer.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Pumitamig Plus Chemo Demonstrates Encouraging Efficacy in Frontline NSCLC
2
Oral Administration Afforded by CDK2 Inhibitors May Ease the Price of Admission in Platinum-Resistant Ovarian Cancer
3
MAIC Shows Improved PFS With Zanubrutinib Over Ibrutinib in Treatment-Naive CLL
4
Dr Randall on the Clinical Utility of Tumor-Informed ctDNA Deep Sequencing for Osteosarcoma Surveillance
5